Empagliflozin
Empagliflozin is an inhibitor of the sodium-glucose co-transporter 2 (SGLT2), the primary transporter responsible for renal glucose reabsorption. By inhibiting SGLT2, empagliflozin reduces renal reabsorption of filtered glucose and lowers the renal threshold for glucose, thereby increasing urinary glucose excretion and lowering blood glucose levels.
Dosage by Body Weight
The recommended starting dose is 10 mg orally once daily in the morning, taken with or without food. In patients tolerating 10 mg daily who require additional glycemic control, the dose may be increased to 25 mg once daily. Renal function (eGFR) must be assessed prior to initiation and periodically thereafter.
- Body Weight
- Below 5 kg
- Dose
- Not recommended
- Frequency
- N/A
- Tracking Notes
- Safety and effectiveness have not been established in this weight range.
- Body Weight
- 5-7 kg
- Dose
- Not recommended
- Frequency
- N/A
- Tracking Notes
- Safety and effectiveness have not been established in this weight range. Not approved for children under 10 years of age.
- Body Weight
- 8-10 kg
- Dose
- Not recommended
- Frequency
- N/A
- Tracking Notes
- Safety and effectiveness have not been established in this weight range. Not approved for children under 10 years of age.
- Body Weight
- 11-15 kg
- Dose
- Not recommended
- Frequency
- N/A
- Tracking Notes
- Safety and effectiveness have not been established in this weight range. Not approved for children under 10 years of age.
- Body Weight
- 16-20 kg
- Dose
- Not recommended
- Frequency
- N/A
- Tracking Notes
- Safety and effectiveness have not been established in this weight range. Not approved for children under 10 years of age.
| Body Weight | Dose | Frequency | Tracking Notes |
|---|---|---|---|
| Below 5 kg | Not recommended | N/A | Safety and effectiveness have not been established in this weight range. |
| 5-7 kg | Not recommended | N/A | Safety and effectiveness have not been established in this weight range. Not approved for children under 10 years of age. |
| 8-10 kg | Not recommended | N/A | Safety and effectiveness have not been established in this weight range. Not approved for children under 10 years of age. |
| 11-15 kg | Not recommended | N/A | Safety and effectiveness have not been established in this weight range. Not approved for children under 10 years of age. |
| 16-20 kg | Not recommended | N/A | Safety and effectiveness have not been established in this weight range. Not approved for children under 10 years of age. |
Formulation
Purpose
Empagliflozin is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus. It is also used to reduce the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease, and to reduce the risk of cardiovascular death and hospitalization in adults with heart failure.
Generic Name
EmpagliflozinBranded Drug Names
Empagliflozin is listed as a generic drug name. Common branded medicines that may contain the same active ingredient include:
Scheduled Drug
Yes. This medicine should be supplied or used only according to applicable prescription and regulatory requirements.